Finally, the majority of trial participants were White women
"Most importantly, GLP-1 medications should be viewed as part of a comprehensive treatment plannot a standalone solution," she said
Available in 5mg/5mg and 10mg/3mg lyophilized vials
Lilly shares, Risinger observed, may be bound within that range near-term pending data from studies of two potential competitors to Mounjaro and Zepbound: Novo Nordisks Phase III candidate CagriSema and Amgen (NASDAQ: AMGN) s obesity candidate Maridebart Cafraglutide (MariTide), which is now in Phase II and wowed investors earlier this year
Any blood sugar improvements come indirectly through weight loss, which helps the body respond better to insulin
In August 2025, Novo Nordisk announced that the FDA has approved WEGOVY as the first GLP-1 receptor agonist for adults with Metabolic Dysfunction-associated Steatohepatitis (MASH) who have moderate to advanced fibrosis, excluding cirrhosis, in combination with diet and exercise
